Evidence map›Paper›PMID 39928243›Full record

Observational studyAdvances in therapy2025

Real-World Multicenter Registry to Determine Management and Quality of Care of Patients with Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases in China (iCaReMe China).

Xiaoling Cai, Wenjia Yang, Bo Feng, Qiuhe Ji, Ming Liu, Yanbing Li, Nanwei Tong, Ningling Sun, Minghui Zhao, Linong Ji

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoling CaiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Wenjia YangDepartment of Endocrinology and Metabolism, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Bo FengDepartment of Endocrinology, Shanghai East Hospital, Tongji University, Shanghai, 200120, China.
Qiuhe JiDepartment of Endocrinology, Xi'an International Medical Center Hospital, Xi'an, 710100, Shanxi, China.
Ming LiuDepartment of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Yanbing LiDepartment of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China.
Nanwei TongDepartment of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, 610041, China.
Ningling SunDepartment of Hypertension, Peking University People's Hospital, Beijing, 100044, China.
Minghui ZhaoRenal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, 100034, China.
Linong JiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. jiln@bjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis article describes the study rationale and design of the real-world multicenter registry study iCaReMe China.

methodsiCaReMe China is a prospective, multicentric, observational registry study aiming to understand the real-world characteristics of patients with type 2 diabetes (T2D) and/or hypertension (HTN) [combined chronic kidney disease (CKD)] and/or heart failure (HF) and/or CKD, which may provide some evidence for improving quality of care and outcomes of T2D and/or HTN and/or HF and/or CKD in China. A total of approximately 19,000 subjects will be recruited from 110 participating sites in China. Patients will be enrolled in four disease cohorts based on the primary disease conditions. The primary outcome is to describe the sociodemographic, clinical characteristics, disease management patterns, healthcare resource utilization, and clinical outcomes.

conclusioniCaReMe China aims to describe the real-world characteristics and treatment patterns of patient with T2D and/or HTN (combined CKD) and/or HF and/or CKD. The data from this prospective registry study will facilitate a better understanding of management strategies, the variations across and within different regions, and associated patient outcomes in China. TRIAL REGISTRATION NUMBER: ChiCTR2300073764.

Indexed as

Diabetes Mellitus, Type 2Heart FailureHypertensionQuality of Health CareRegistriesRenal Insufficiency, ChronicAgedChinaFemaleHumansMaleMiddle AgedProspective StudiesCardiovascular diseaseChronic kidney diseaseHeart failureReal-world registry studyType 2 diabetes

Identifiers

PMID39928243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.